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Background: In vivo studies show that cannabidiol (CBD) acutely reduces blood pressure 2 
(BP) in men. The aim of this study was to assess the effects of repeated CBD dosing on 3 
haemodynamics. 4 
Methods: 26 healthy males were given CBD (600mg) or placebo orally for seven days in a 5 
randomised, placebo-controlled, double-blind, parallel study (n=13/group). Cardiovascular 6 
parameters were assessed at rest and in response to isometric exercise after acute and 7 
repeated dosing using Finometer®, Vicorder® and Duplex ultrasound. 8 
Results: Compared to placebo, CBD significantly reduced resting mean arterial pressure 9 
(p=0.04, 2-way ANOVA, mean difference (MD) -2 mmHg, 95% CI -3.6 to -0.3) after acute 10 
dosing, but not after repeated dosing. In response to stress, volunteers who had taken CBD 11 
had lower systolic BP after acute (p=0.001, 2-way ANOVA, MD -6 mmHg, 95% CI -10 to -1) 12 
and repeated (p=0.02, 2-way ANOVA, MD -5.7 mmHg, 95% CI -10 to -1) dosing. Seven days 13 
of CBD increased internal carotid artery diameter (MD +0.55 mm, p=0.01).  Within the CBD 14 
group, repeated dosing reduced arterial stiffness by day seven (pulse wave velocity; MD -15 
0.44 m/s, p=0.05) and improved endothelial function (flow mediation dilatation, MD +3.5%, 16 
p=0.02, n=6 per group), compared to day one.  17 
Conclusion: CBD reduces BP at rest after a single dose but the effect is lost after seven days 18 
of treatment (tolerance); however, BP reduction during stress persists. The reduction in 19 
arterial stiffness and improvements in endothelial function after repeated CBD dosing are 20 
findings that warrant further investigation in population with vascular diseases.  21 
 22 
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What is already known:  1 
• Pre-clinical studies have shown that CBD causes vasorelaxation of isolated arteries 2 
and reduces vascular inflammation. 3 
• In vivo studies show that CBD acutely reduces blood pressure in men 4 
What the study adds: 5 
• This study assessed the effects of repeated CBD dosing on haemodynamics, 6 
tolerance and other vascular endpoints in healthy males. 7 
• Cannabidiol reduces blood pressure at rest after a single dose, in response to stress 8 
after a single and repeated doses, and potentially improves endothelial function and 9 
arterial stiffness. 10 
• Further research is needed to investigate the cardiovascular effects of CBD in 11 
populations with cardiovascular disease.  12 
  13 
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INTRODUCTION  1 
Cannabidiol (CBD), the second most abundant phytocannabinoid found in the Cannabis 2 
sativa plant, shows desirable effects in clinical conditions including anxiety and epilepsy [1-3 
3]. Epidiolex® (CBD based medicine) is already licenced and approved by Food and Drug 4 
Administration for children with Dravet and Lennox-Gastaut syndrome. CBD displays low 5 
affinity for cannabinoid receptors (cannabinoid receptor 1 and 2, CB1 and CB2) and activity 6 
at non-cannabinoids receptor sites, including transient receptor potential vanilloid receptors 7 
(TRPs), peroxisome proliferator-activated receptors (PPARs), G protein-coupled receptor 55 8 
(GPR55) and 5-hydroxytryptamine (5HT) [4, 5].  9 
Preclinical studies have shown beneficial effects of CBD on the vasculature [5]. CBD reduces 10 
cerebral vascular inflammation and associated dilatation induced by lipopolysaccharide in 11 
mice [6], enhances blood brain barrier permeability in in vitro models of stroke [7], and 12 
reduces infarct size in animal models of stroke [8]. These effects are mediated at least in 13 
part by PPARγ and 5HT1A [5]. CBD also decreases myocardial infarct size in a rat model of 14 
ischaemia/reperfusion injury [9]; attenuates myocardial dysfunction and inflammation in 15 
animal models of diabetes through independent-cannabinoid receptor mechanisms [10]; 16 
and improves vasorelaxation in the femoral arteries of Zucker diabetic fatty rats via 17 
enhanced production of vasodilator COX-1/2-derived products acting at EP4 receptors [11, 18 
12]. Together, these studies suggest a potential benefit of CBD in cardiovascular disorders. 19 
CBD also alters the blood pressure, heart rate and blood flow in animals; CBD increased 20 
heart rate and mean blood pressure in anaesthetised dogs [13, 14], caused bradycardia in 21 
conscious monkeys [15], reduces blood pressure in rats with cardiac ischaemia [16], and 22 
increases cerebral blood flow in murine models of stroke [17]. Our recent systematic review 23 
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and meta-analysis of the in vivo haemodynamic effects of CBD has shown that acute and 1 
chronic dosing of CBD had no effect on haemodynamics under non-stress conditions, 2 
reduces the increase in BP and HR in response to stress, and increases cerebral blood flow in 3 
murine models of stroke [18]. This study also highlighted the limited number of studies 4 
investigating the haemodynamic and regional blood flow impact of CBD administration in 5 
humans. To help address this, we recently showed that a single dose of CBD (600 mg) causes 6 
a reduction in blood pressure at rest and in response to stress in healthy males [19]. The aim 7 
of this study was to establish if we could replicate the findings and examine whether the 8 
response was affected by repeated dosing with CBD.  9 
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METHODS     1 
Study design 2 
We performed a randomised, placebo controlled, double blind, parallel group trial with each 3 
participant received an oral dose of either placebo (control) or CBD (600 mg per day) for 4 
seven consecutive days. The dose of CBD was chosen based on our recent study [19]. The 5 
trial was conducted in accordance with the Declaration of Helsinki and the International 6 
Conference of Harmonisation of Good Clinical Practice (ICH-GCP), was sponsored by the 7 
University of Nottingham, UK, and approved by the University of Nottingham’s Faculty of 8 
Medicine & Healthy Sciences Research Ethics Committee (Reference No: E1411201). Written 9 
informed consent was taken from all participants, who were recruited between September 10 
2017 and July 2018 11 
All measures, visits and analyses were performed blinded to treatment allocation. 12 
Randomisation was performed using computerised random number generation. TJE 13 
assigned participants and SRS carried out all study visits.  14 
Intervention 15 
The placebo and CBD provided by Phivida Neutrafuels (Lot number 0717PV 0101). 16 
Primary outcome and Sample size 17 
In our previous study [19], CBD reduced resting systolic blood pressure by 6 mmHg in nine 18 
healthy male volunteers. The main aim of the study was to determine if the changes in 19 
blood pressure, seen after a single dose, persisted after repeated dosing. We aimed to 20 
recruit 13 participants per group, which provided 80% power to detect a 5 mmHg difference 21 
(a clinically meaningful reduction) in systolic blood pressure (primary outcome) after 1 week 22 
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between groups (assuming a standard deviation 4.5 mmHg and alpha 0.05). All other 1 
vascular endpoints assessed in this study are considered as secondary outcomes.   2 
Participants   3 
For this study, healthy men with no underlying medical conditions, not on regular 4 
medications and not exposed to cannabis within the last month were included. Women 5 
were excluded due to the potential gender differences in response to CBD [20, 21].  6 
Cardiovascular parameters  7 
Haemodynamic parameters were assessed non-invasively after day one and day seven of 8 
receiving the drug. Blood pressure (BP) and other parameters, including heart rate (HR), 9 
stroke volume (SV), cardiac output (CO), ejection time (ET) and total peripheral resistance 10 
(TPR) were measured at rest and during isometric exercise using a Finometer®. Aortic blood 11 
pressure was measured from the brachial site by pulse wave analysis (PWA).  12 
Arterial stiffness 13 
Arterial stiffness was measured through pulse wave velocity (PWV) between the carotid and 14 
femoral anatomical sites using Vicorder®.   15 
Blood flow and endothelial function  16 
Duplex ultrasound and Cardiovascular suite Quipu software were used to measure blood 17 
vessel diameter (D) and blood flow (BF) velocities of the common carotid artery (CCA), 18 
internal carotid artery (ICA), and brachial artery (BA); and endothelial function through flow 19 
mediation dilatation (FMD) of the brachial artery were assessed using a linear probe (L15-4 20 
MHz) of high resolution ultrasound (Terason 3200T) [22-24]. For the CCA, the Doppler 21 
sample volume was placed 1-2 cm proximal to the carotid bifurcation. The ICA Doppler 22 
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sample was placed 1-2 cm distal to the bifurcation or at the most distal segment where the 1 
artery is uniform [25]. Doppler information for the brachial artery was measured 1-2 cm 2 
proximal the angle in which the brachial artery dives in to cubital fossa. The diameter of 3 
CCA, ICA and BA were measured at the same location in which the Doppler information was 4 
measured using automated edge-detection software (Cardiovascular suite Quipu). The BF 5 
volume within the ICA, CCA, and BA was calculated using following equation: BF volume 6 
(l/min) = ((peak systolic velocity/2) X area X 60)/1000 to compare relative flow volumes 7 
among the participants in the present study. The area (A) was determined from the artery 8 
diameter (D) using the equation: A = D2 x 0.78 [26, 27]. The left middle cerebral artery 9 
(MCA) was assessed by measuring the blood flow velocities using a low frequency 10 
transcranial Doppler (TCD) probe (2 MHz) of Sonora Transcranial Doppler System.   11 
24-hour Ambulatory Blood Pressure Monitoring 12 
24-hour Ambulatory Blood Pressure Monitoring (ABPM; TM-2430) was used to provide 13 
continuous blood pressure measurements away from the clinical assessment room. The 14 
device was set to take measurements every 30 minutes through the day time (9 am – 11 15 
pm), and every hour through the night (11pm – 8am) [28]. Participants were given the 16 
option to wear the ABPM device on day 6 and were asked to keep their arm still at the level 17 
of their heart when the device started to take a reading [29].  18 
Study assessment  19 
Each participant attended a clinical assessment room at the Division of Medical Sciences and 20 
Graduate Entry Medicine & Health, University of Nottingham in the Royal Derby Hospital 21 
three times plus an additional optional visit for the ABPM.  22 
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The vascular function can be affected by medications, food supplements, caffeine, smoking 1 
and temperature [30, 31]. Participants were asked to attend having fasted overnight, with 2 
no vitamin supplementations for 72 hours and avoiding exercise, caffeine, alcohol and 3 
cigarette smoking for the previous 24 hours [32]. 4 
During the initial visit, subjects were screened for eligibility and provided written informed 5 
consent. On day one of receiving the drug or placebo, height and weight were measured 6 
and participants were asked to lie in supine position with their head slightly elevated on a 7 
bed for 15 minutes. The Finometer® was then attached to the participant`s left index finger 8 
and cardiovascular parameters were recorded continuously for three hours at rest. Baseline 9 
readings were recorded over 15 minutes before the participants took either placebo or CBD 10 
(600 mg). Two hours later, the effects of the drug/placebo on blood flow, endothelial 11 
function, aortic blood pressure and arterial stiffness were measured. During these two 12 
hours, participants were allowed to watch television, use a computer or read. Two hours 13 
after drug administration, participants were asked to perform isometric handgrip (IHG) 14 
stress exercise for three minutes [33] by using a dynamometer with their right hand while 15 
the Finometer® was continuously recording. The assessment on both study visits (day one 16 
and day seven) took place in the same assessment room at a temperature ~ 22◦ Celsius.  On 17 
day seven (last day of receiving the drug), the same protocol was followed. 18 
CBD/placebo tolerance was assisted with a subject diary including any side effects they may 19 
have experienced.   20 
Statistical analysis   21 
All statistical analysis was performed using IBM SPSS Statistics (Version 21.0. Armonk, NY: 22 
IBM Corp) and PRISM 7 (GraphPad, Software, La Jolla, CA, USA). The level of significance was 23 
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set at 0.05. Variables were tested for normality by assessing the data distribution on a 1 
histogram. Repeated measures two-way ANOVA determined the effect of treatment on 2 
blood pressure and other cardiovascular parameters measured with Finometer®. Sidak`s 3 
post-hoc tests were used to determine changes at specific time points. For all variables, 4 
Paired and Unpaired t-tests were used for comparison between related and independent 5 
samples, respectively.  6 
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RESULTS    1 
Twenty-six healthy men were recruited (13 subjects in each group). 11 of 26 subjects were 2 
previous cannabis users (CBD, n=8; placebo, n=3), but were abstinent from cannabis for a 3 
period ranging from 2 months to 1 year pre-study.  The age, weight, height and BMI of 4 
participants who received CBD were: 26.3 ± 5.6 years, 80.1 ± 9.9 kg, 1.8 ± 0.1 m and 25 ± 2 5 
respectively; and participants who received placebo: 27 ± 6 years, 82.1 ± 9.8 kg, 1.8 ± 0.1 m 6 
and 25.7 ± 2.9 (mean ± SD).  7 
Blood pressure and other cardiovascular parameters  8 
Acute dosing of CBD treatment at rest did not significantly reduce systolic BP (SBP p=0.08) 9 
or diastolic BP (DBP p=0.09) (Figure 1A, B), but significantly reduced mean arterial pressure 10 
(MAP) (p=0.04, 2-way ANOVA, Figure 1C; mean difference (MD) -2 mmHg, 95% CI -3.6 to -11 
0.3), without affecting other cardiovascular parameters compared to placebo (Figure 1D-H). 12 
There was no effect on SBP, DBP or MAP at rest following chronic CBD dosing (Figure 2) 13 
suggesting the development of tolerance. Participants’ SBP readings obtained pre-14 
CBD/placebo on day one and day seven are presented in Suppl. Table 1 and Suppl. Figure 1. 15 
Isometric exercise caused a significant increase in BP in the two treatment groups (Figures 3 16 
and 4). SBP was significantly lower in CBD treated group compared to placebo group after 17 
single (p=0.001, 2-way ANOVA, Figure 3A; MD -6 mmHg, 95% CI -10 to -1) or repeated CBD 18 
dosing (p=0.02, 2-way ANOVA, Figure 4A; MD -5.7 mmHg, 95% CI -10 to -1). Sidak post-hoc 19 
analysis showed that acute CBD dosing significantly lowered SBP at minutes’ two (MD -6.6 20 
mmHg, 95% CI -12.7 to -0.4, p=0.02, Figure 3A) and three (MD -6.5 mmHg, 95% CI -12.7 to -21 
0.3, p=0.03, Figure 3A) during stress. After seven days of CBD dosing, the mean difference in 22 
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SBP compared to placebo was -8 mmHg (95% CI -15.7 to -0.57, p=0.02, Figure 4A) at the first 1 
minute of stress. 2 
24-hour Ambulatory Blood Pressure Monitoring 3 
After 6 days treatment with CBD, there was no difference in the 24-ABPM between the two 4 
treatment groups (Figure 5 A-C).  5 
Aortic blood pressure and arterial stiffness  6 
There was no difference in aortic BP (CBD n=9; placebo n=8 on day 1 and n=9/group on day 7 
7, Figure 6A, B) or arterial stiffness (n=10 in each group, Figure 6C) between the two 8 
treatment groups at rest after acute or repeated dosing. Paired t-test showed that CBD 9 
dosing for 7 days significantly reduced arterial stiffness (PWV: MD -0.44 m/s, 95% -0.01 to 10 
0.9, p=0.05, Figure 6C) compared to a single CBD dosing received on day one. 11 
Blood flow and endothelial function  12 
CBD dosing for seven days increased ICA-diameter (MD +0.55 mm, 95% CI 0.1 to 0.9, p=0.01, 13 
Figure 7B) without causing a significant increase in ICA-BFV (p=0.07) compared to placebo, 14 
at rest. Repeated CBD dosing also significantly increased ICA-diameter (MD +0.43 mm, 95% 15 
CI -0.8 to 0, p=0.05, Figure 7B), and significantly increases FMD (MD +3.5%, 95% CI -6.2 to -16 
0.6, p=0.02, n= 6 in each group, Figure 8C) compared to the same group treated with CBD 17 
after a single dose on day one. No differences were seen in MCA velocity, or CCA and BA 18 
parameters between the two groups post-treatment (see Suppl. Figure 2 A-G). 19 
Side effects 20 
Side effects reported post-CBD administration included lack of appetite on day 4 (n=1), 21 
headache on day 3 (n=1), insomnia on days 2 and 3 (n=1), hyperactivity on days 2 and 3 22 
13 
 
(n=1), and dysuria on days 5 and 6 (n=1). Following placebo administration, subjects 1 
reported migraine on day 4 (n=1) and light-headedness on day 6 (n=1).   2 
14 
 
Discussion  1 
The aim of this study was to investigate the effects of acute and repeating dosing of CBD on 2 
the cardiovascular system in healthy males. Compared to a placebo, CBD significantly 3 
reduced MAP at rest but not after repeated dosing. In response to isometric exercise, there 4 
was a lower SBP response after both acute and repeated dosing. We also found that 5 
repeated CBD dosing increases ICA-diameter and may improve endothelial function and 6 
arterial stiffness. These findings suggest that CBD might benefit vascular function, 7 
particularly under stress, and further work is required to investigate the effects of CBD in 8 
humans under pathological conditions.   9 
We previously showed that a single dose of CBD decreases resting BP and increases HR in 10 
cannabis naïve men [19]. The effect on BP was reproduced in the present study, but this 11 
effect was lost after repeated dosing suggesting that tolerance develops. However, the 12 
increase in HR post-CBD was not reproduced here. THC, the major component of cannabis, 13 
can induce tachycardia in humans through CB1 activation [34]. It is possible that CBD could 14 
induce tachycardia through a similar mechanism, although CBD stimulates several receptors 15 
and is a weak CB1 agonist. Explaining the difference in findings on the effect of CBD on HR 16 
between our two studies is challenging as the protocols were so similar in terms of dose, 17 
population (young males) and methods of measurement. However, variability in ‘activity’ 18 
during the resting phase could be contributory (e.g. reading versus watching the TV). 19 
Further, unmeasured variables such as ethnicity and genetic factors (polymorphisms) may 20 
account for the difference and deserves attention in future studies. Of note, post-hoc 21 
analyses did not show any differences in HR between previous cannabis users and those 22 
who were cannabis naïve.  23 
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The reduction in BP may be secondary to CBD anti-anxiolytic properties [2, 35] preventing 1 
the increase in BP which was seen in the placebo group on the first day of receiving the 2 
treatment (see Suppl Figure 3). A number of previous human studies, in which their primary 3 
aim was not to investigate the effect of CBD on BP, reported that there were no changes on 4 
BP or HR post-CBD administration. It is important, however, to note that these studies 5 
assessed BP and HR by taking a single measurement manually at different time points post-6 
treatment, whereas cardiovascular parameters were measured continuously for 3 hours 7 
post-treatment in the present study.   8 
A CBD dose of 600 mg was chosen based on our previous study [19]. A wide range of doses 9 
have been used in other conditions, highlighted in our recent systematic review [36], 10 
including epilepsy, schizophrenia, dystonia, social anxiety and post-traumatic stress 11 
disorders. The average CBD dose that reported positive effects in the assessed conditions 12 
ranged between 14-23 mg/kg/day. A CBD dose of 14 mg/kg/d would be equivalent to a dose 13 
of 1,120 mg in an 80 kg human (the mean weight of participants in the present study). 14 
Overall, there is limited information on the efficacy, pharmacokinetics and 15 
pharmacodynamics of cannabis derived medicines [37], and dose-escalation trials in people 16 
with  cardiovascular diseases are required. 17 
In response to stress-induced hypertension, our findings showed that CBD reduced the 18 
increase in BP during isometric exercise after acute and repeated dosing, as we previously 19 
observed after a single dose [19]. We note that for the hand-grip experiment, the groups 20 
start to diverge prior to exercise initiation with no difference between groups at baseline -3 21 
minutes pre-stress (Sidak`s post-hoc analyses p=0.8) compared to -1 minute (p=0.06). It is 22 
feasible that CBD also suppresses the anticipation of the expected stress and therefore the 23 
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groups diverge from each other prior to the exercise itself. Pre-clinical studies on animals 1 
models of stress showed that CBD reduces anxiety through the activation of 5HT1A and CB1 2 
receptors [38, 39]. CBD activation of 5HT1A in rats also reduces the increase in BP induced by 3 
stress [40, 41]. Our systematic review and meta-analysis also suggested that CBD alters BP 4 
under stressful conditions, but not under resting conditions [18]. In this study, CBD’s 5 
hypotensive effect in response to stress persisted after repeated dosing, a finding that 6 
warrants further research into conditions affecting the cardiovascular system.  7 
Our results indicate, for the first time in humans, that CBD increases ICA-diameter with an 8 
associated tendency to increase ICA-BFV. This effect was only observed after repeated and 9 
not after single dosing. A related effect of CBD has been reported in pre-clinical studies [42, 10 
43], in that neuroprotection induced by CBD in murine models of stroke was seen in 11 
association with an increase in cerebral blood flow, with no tolerance developing after 12 
chronic treatment for 14 days [43, 44]. These effects were inhibited with the administration 13 
of 5HT1A antagonist [43, 45]. Another study in piglets with brain injury reported that 5HT1A 14 
and CB2 have a role in CBD induced neuroprotection [42]. Our study showed that CBD had 15 
no effect in the MCA blood flow velocities assessed using TCD; however, testing MCA 16 
velocity at a single time point in our small sample is unlikely to be sufficiently sensitive to 17 
detect subtle changes in cerebral autoregulation in a healthy brain. This was an exploratory 18 
measure since it is recognised that CBD can alter regional cerebral blood flow in other 19 
conditions, e.g. in social anxiety disorder [46]. Taken together, the effects we have seen that 20 
CBD has on BP acutely, under stress, on endothelial function, and on arterial stiffness, in 21 
conjunction with pre-clinical stroke data showing improvements in CBF, suggests further 22 
investigation in a stroke population is warranted. 23 
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Repeated CBD administration for seven days increased FMD and may improve endothelial 1 
function. This should be interpreted with caution, however, since (i) this difference was 2 
observed within the CBD group (Day 1 versus Day 7) rather than between CBD and placebo 3 
groups; (ii) the change occurred in the absence of a BP change over 7 days; and (iii) we do 4 
not have any pre-treatment PWV values in either group. CBD stimulates the production of 5 
nitric oxide (NO) causing endothelium-dependent vasorelaxation of isolated human arteries 6 
through CB1 activation [47], and a meta-analysis on the association of FMD and NO 7 
demonstrates that FMD is significantly mediated by NO [48]. Therefore, CBD may improve 8 
endothelial function through a NO-dependant mechanism via the activation of CB1. The 9 
same mechanism might be responsible for the potential reduction in arterial stiffness seen 10 
after repeated doses of CBD; PWV is a recognised surrogate marker of cardiovascular 11 
disease with a 1 m/s in PWV decrease correlating with a reduction in the risk of 12 
cardiovascular events by 10% [49]. This signal of reduction in arterial stiffness and the 13 
improvement endothelial function after repeated CBD dosing are markers indicating a 14 
positive effect on vascular function. However, structural arterial changes and improvements 15 
in vascular stiffness after just seven days is unexpected and further studies should also 16 
assess later time-points and biomarkers of collagen and elastin turnover. 17 
Our study has many strengths including a robust study design, randomisation, concealment 18 
of allocation and blinding both the volunteers and the investigator. We considered a cross-19 
over design as we did in our initial acute dosing study (rather than parallel group) but felt a 20 
prolonged length of involvement for each participant would have limited recruitment 21 
sufficiently to impair trial accrual. We should also accept some other limitations: (i) data 22 
should be interpreted with caution due to the small sample size, and (ii) CBD effects on ICA 23 
diameter, endothelial function and arterial stiffness were only seen when compared to 24 
18 
 
values after a single CBD dose, not when compared to placebo. Further investigation in 1 
larger sample sizes, in women, and diseased populations are required.  2 
Conclusion   3 
CBD reduced MAP after acute dosing at rest, and reduced SBP after acute and repeated 4 
dosing in response to stress-induced hypertension in healthy male volunteers. Seven days of 5 
CBD increased ICA diameter appeared to improve endothelial function and arterial stiffness. 6 
These findings suggest that CBD may be a potential treatment for cardiovascular disease 7 
and further studies are warranted.  8 
 9 
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Figure Legends 1 
Figure 1 Cardiovascular parameters at rest after acute dosing (day 1). Systolic blood pressure (SBP) 2 
(A), diastolic blood pressure (DBP) (B), mean arterial pressure (MAP) (C), heart rate (HR) (D), cardiac 3 
output (CO) (E), stroke volume (SV) (F), ejection time (ET) (G), and total peripheral resistance (TPR) 4 
(H) were measured continuously for 3 hours after drug ingestion (↑) using Finometer (n=13). Closed 5 
circle is CBD group and opened square is placebo group. Repeated measure two-way ANOVA (* 6 
p≤0.05); data is presented as mean±SEM.   7 
 8 
Figure 2 Cardiovascular parameters at rest after 7 days CBD treatment. Systolic blood pressure 9 
(SBP) (A) , diastolic blood pressure (DBP) (B), mean arterial pressure (MAP) (C) and heart rate (HR) 10 
(D) measured continuously after drug ingestion (↑) using Finometer on day 7 (n=13). Closed circle is 11 
CBD group and opened square is placebo group; mean±SEM. No significant difference between the 12 
treatment groups. 13 
 14 
Figure 3 Cardiovascular parameters in response to exercise stress after acute dosing (day 1). 15 
Systolic blood pressure (SBP) (A) , diastolic blood pressure (DBP) (B), mean arterial pressure (MAP) 16 
(C), heart rate (HR) (D), cardiac output (CO) (E), stroke volume (SV) (F), ejection time (ET) (G), and 17 
total peripheral resistance (TPR) (H) measured continuously using Finometer on day 1; pre, during 18 
and post-isometric exercise stress (n=13). Closed circle is CBD group and opened square is placebo 19 
group. Repeated measure two-way ANOVA (* p≤0.05); mean± SEM (# p≤0.05 using Sidak post-hoc 20 
analysis between CBD and placebo groups).  21 
 22 
Figure 4 Cardiovascular parameters in response to exercise stress after 7 days CBD treatment. 23 
Systolic blood pressure (SBP) (A) , diastolic blood pressure (DBP) (B), mean arterial pressure (MAP) 24 
(C), heart rate (HR) (D), cardiac output (CO) (E), stroke volume (SV) (F), ejection time (ET) (G), and 25 
total peripheral resistance (TPR) (H) measured continuously using Finometer on day 7; pre, during 26 
and post-isometric exercise stress (n=13). Closed circle is CBD group and opened square is placebo 27 
group. Repeated measure two-way ANOVA (* p≤0.05); mean±SEM (# p≤0.05 using Sidak post-hoc 28 
analysis between CBD and placebo groups).   29 
 30 
Figure 5 24-hour Ambulatory Blood Pressure Monitoring at rest after 6 days CBD treatment. 31 
Systolic blood pressure (SBP) (A),  diastolic blood pressure (DBP) (B) and Mean arterial pressure 32 
(MAP) (C) were measured using an Ambulatory Blood Pressure device (AMBP) for 24 hours on day 6 33 
of receiving the treatment (CBD group n=10 and placebo group n=7). Closed circle is CBD group and 34 
opened square is placebo group; mean ± SEM. No significant difference between the treatment 35 
groups. 36 
 37 
Figure 6 Aortic blood pressure and arterial stiffness after the first (day 1) and seventh dose of CBD. 38 
Aortic systolic blood pressure (Ao-SBP) (A), aortic diastolic blood pressure (Ao-DBP) (B) (n=9 in CBD 39 
group, and n=8 and 9 in placebo group at day 1 and 7, respectively), and pulse wave velocity (PWV) 40 
(D) (n=10) measured using Vicorder 2 hours after acute dosing on day 1 (D1) and chronic dosing on 41 
day 7 (D7); mean±SEM (* p≤0.05 using Paired t-test between related groups post-drug ingestion). 42 
 43 
 44 
Figure 7 Internal carotid artery response after the first (day 1) and seventh dose of CBD. Internal 45 
carotid artery blood flow volume (ICA-BFV) (A), diameter (ICA-D) (B) and peak systolic velocity (ICA-46 
PSV) (C) (n=13) measured using ultrasound 2 hours after acute dosing on day 1 (D1) and chronic 47 
dosing on day 7 (D7); mean±SEM (*p≤0.05 using Paired t-test between related groups, and Unpaired 48 




Figure 8 Endothelial function response after the first (day 1) and seventh dose of CBD. Brachial 1 
artery diameter (BA-D) at baseline (BL) (A) and post-occlusion (PO) (B) and Flow mediation dilatation 2 
(FMD) (C) (n=6) measured using ultrasound 2 hours after acute dosing on day 1 (D1) and chronic 3 
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Suppl. Table 1 Participant pre-drug systolic blood pressure on day 1 and 7. Pre-CBD Systolic 




























Suppl. Figure 1 Participant baseline (BL) pre-drug systolic blood pressure (SBP) of CBD and 

























































































Suppl. Figure 2 Cerebral and brachial artery blood flow after acute and 7 days CBD 
treatment. Middle cerebral artery blood flow peak systolic velocity (MCA-PSV) (A), 
common carotid artery blood flow volume (CCA-BFV) (B), diameter (CCA-D) (C) and 
peak systolic velocity (CCA-PSV) (D), brachial artery blood flow volume (BA-BFV) (E), 
diameter (BA-D) (F) and peak systolic velocity (BA-PSV) (G) measured using ultrasound 
2 hours after acute dosing on day 1 (D1) and chronic dosing on day 7 (D7) (n=13 in each 






















































































































































































































Suppl. Figure 3 Blood pressure at rest after acute and chronic dosing. Systolic blood 
pressure (SBP) (A) , diastolic blood pressure (DBP) (B) and mean arterial pressure 
(MAP) (C) after single ( D1) and repeated dosing for 7 days (D7) at rest (n=13 in each 
group); mean ± SEM (* p≤0.05 using additional exploratory Paired t-test between 
related groups and Unpaired t-test between independent groups post-drug 
ingestion). 
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